Insulin Resistance
Conditions
Keywords
Vitamin D, Glucose, HbA1C, Insulin resistance, Blood lipids
Brief summary
The investigators examined the effect of vitamin D supplementation on glucose homeostasis and metabolic markers in healthy normal weight and overweight young subjects and healthy normal-weight and overweight elderly subjects living in Beirut, Lebanon.
Detailed description
A low serum 25-hydroxyvitamin D (25(OH)D) concentration has been shown to correlate with higher fasting blood glucose (FBG) and insulin levels and other metabolic abnormalities like dyslipidemia. Previous studies suggest that vitamin D supplementation is able to improve insulin sensitivity and metabolic markers. The aim of the study was to investigate the effect of vitamin D supplementation on glucose homeostasis and metabolic markers in healthy normal weight and overweight young subjects and healthy normal-weight and overweight elderly subjects living in Beirut, Lebanon. Participants (n= 180; 93 men and 87 women) deficient in vitamin D were recruited from Saint Charles Hospital, Beirut, Lebanon. Four groups were recruited: normal-weight adults (n=30, age ≤ 65 years and BMI \< 25 kg/m²), overweight adults (n=30, age ≤ 65 years and BMI ≥ 25 kg/m²), normal-weight elderly (n=60, age ≥ 65 years and BMI \< 25 kg/m²) and overweight elderly (n=60, age ≥ 65 years and BMI ≥ 25 kg/m²). Participants received a supplement of 10,000 IU cholecalciferol to be taken three times per week for a period of 6 months. Glucose homeostasis and metabolic markers were measured at start of treatment, at 3 months and at 6 months.
Interventions
All assigned patients received a supplement of 10,000 IU cholecalciferol (Euro-Pharm International, Canada) to be taken three times per week. The treatment was led for a period of 6 months.
Sponsors
Study design
Eligibility
Inclusion criteria
* Participants with no medical history of congestive heart failure, acute heart insufficiency and renal failure were included
Exclusion criteria
* Participants with medical history of congestive heart failure, acute heart insufficiency and renal failure were excluded
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Fasting blood glucose (mmol/l) | Baseline and 6 months | Change in Fasting blood glucose in mmol/l |
| HbA1C (%) | Baseline and 6 months | Change in HbA1C (%) |
| HOMA-IR | Baseline and 6 months | Change in HOMA-IR |
| Fasting Insulin (mIU/L) | Baseline and 6 months | Change in Fasting Insulin (mIU/L) |